Figure 5
Salirasib and Cadnesartan inhibit PRL-3 mediated cell migration in human colorectal cancer cells. (a) Representative images of migration of the human colorectal cancer cell line HCT116 when treated with 1% DMSO, 100 µM Salirasib or 25 µM Candesartan. (b) Quantification (a) across three independent experiments, in triplicate, in both HCT116 and SW480 cells. Migration was measured by quantifying the empty area in the image of the entire well at 0 and 24 h post-scratch using ImageJ and calculating the difference. Percent migration was measured as the area migrated 24 h after scratch normalized to the area migrated by DMSO control. (c) Migration of HCT116 cells that were transfected with either scrambled or PRL-3 shRNA and then treated with 1% DMSO, 100 µM Salirasib or 25 µM Candesartan. Data were quantified as above, except that all data sets were normalized to the Scrambled shRNA transfected cells treated with DMSO. Negative values indicate that the empty area was larger at 24 h than the 0 timepoint. All assays were run in duplicate wells, in 3 independent experiments. Bars indicate the mean percent cell migration, and error bars represent standard deviation between assays. ***p = 0.026 using one-way ANOVA with Tukey’s HSD, *p = 0.039, ****p = 0.0021, **p = 0.02, ns = not significant, analyzed by a two-way ANOVA with Dunnett’s correction.
